Entry |
|
Name |
Dronedarone hydrochloride (USP); Multaq (TN) |
Product |
|
Formula |
C31H44N2O5S. HCl
|
Exact mass |
592.2738
|
Mol weight |
593.22
|
Structure |

|
Simcomp |
|
Class |
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG01456 Adrenergic receptor agonist
DG01653 Antiarrhythmics
DG01648 Class III antiarrhythmic agent
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
Transporter inhibitor
DG01622 ABCB1 inhibitor
|
Remark |
Product (DG00207): | D03914<US> |
|
Efficacy |
Antiarrhythmic |
Comment |
Amiodarone derivative
|
Target |
|
Pathway |
hsa04261 | Adrenergic signaling in cardiomyocytes |
hsa04270 | Vascular smooth muscle contraction |
|
Metabolism |
|
Interaction |
CYP inhibition: CYP3A [HSA: 1576 1577 1551], CYP2D6 [HSA: 1565]
Transporter inhibition: ABCB1 [HSA: 5243]
|
Structure map |
map07232 | Potassium channel blocking and opening drugs |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01B ANTIARRHYTHMICS, CLASS I AND III
C01BD Antiarrhythmics, class III
C01BD07 Dronedarone
D03914 Dronedarone hydrochloride (USP) <US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Antiarrhythmics
Vaughn Williams-Class III
Dronedarone
D03914 Dronedarone hydrochloride (USP)
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
DG01456 Adrenergic receptor agonist
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
DG01653 Antiarrhythmics
DG01648 Class III antiarrhythmic agent
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
DG02852 CYP3A/CYP3A4 inhibitor
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG00207 Dronedarone
D03914 Dronedarone hydrochloride
Drug classes [BR:br08332]
Cardiovascular agent
DG01653 Antiarrhythmics
D03914 Dronedarone hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D03914 Dronedarone hydrochloride (USP) <US>
ADRB1
D03914 Dronedarone hydrochloride (USP) <US>
Ion channels
Voltage-gated ion channels
Calcium channels
CACNA1-L
D03914 Dronedarone hydrochloride (USP) <US>
Potassium channels
KCND3
D03914 Dronedarone hydrochloride (USP) <US>
KCNH2
D03914 Dronedarone hydrochloride (USP) <US>
KCNQ1
D03914 Dronedarone hydrochloride (USP) <US>
Inward rectifier channels (Kir)
KCNJ3
D03914 Dronedarone hydrochloride (USP) <US>
KCNJ5
D03914 Dronedarone hydrochloride (USP) <US>
KCNJ11
D03914 Dronedarone hydrochloride (USP) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03914
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03914
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03914
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03914
Drug transporters
D03914
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG00207 Dronedarone
DG01456 Adrenergic receptor agonist
DG00207 Dronedarone
DG01653 Antiarrhythmics
DG01648 Class III antiarrhythmic agent
DG00207 Dronedarone
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00207 Dronedarone
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00207 Dronedarone
DG02852 CYP3A/CYP3A4 inhibitor
DG00207 Dronedarone
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG00207 Dronedarone
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 40
1 C8y C 22.8367 -17.7635
2 C8x C 22.8367 -19.1718
3 C8x C 24.0563 -19.8760
4 C8y C 25.2760 -19.1718
5 C8y C 25.2760 -17.7635
6 C8x C 24.0563 -17.0594
7 O2x O 26.6154 -19.6070
8 C8y C 27.4432 -18.4677
9 C8y C 26.6154 -17.3284
10 N1b N 21.6172 -17.0594
11 S4a S 20.4146 -17.7539
12 C1a C 19.1949 -18.4580
13 O3c O 21.1296 -18.9929
14 O3c O 19.7219 -16.5537
15 C5a C 26.6154 -15.9201
16 C8y C 27.8471 -15.2087
17 O5a O 25.4191 -15.2294
18 C1b C 28.8220 -18.4677
19 C8x C 29.0672 -15.9128
20 C8x C 30.2867 -15.2085
21 C8y C 30.2863 -13.8002
22 C8x C 29.0664 -13.0960
23 C8x C 27.8468 -13.8004
24 O2a O 31.5077 -13.0947
25 C1b C 32.7291 -13.7996
26 C1b C 33.9139 -13.1152
27 C1b C 35.1174 -13.8099
28 N1c N 36.3111 -13.1205
29 C1b C 37.5100 -13.8127
30 C1b C 38.7060 -13.1219
31 C1b C 29.5262 -17.2481
32 C1b C 30.9343 -17.2481
33 C1a C 31.6289 -16.0454
34 C1b C 36.3110 -11.7080
35 C1b C 37.5118 -11.0146
36 C1b C 38.7052 -11.7034
37 C1a C 39.9039 -11.0110
38 C1b C 39.9037 -13.8134
39 C1a C 41.1003 -13.1223
40 X Cl 36.3300 -18.7600
BOND 41
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 1 10 1
12 10 11 1
13 11 12 1
14 11 13 2
15 11 14 2
16 9 15 1
17 15 16 1
18 15 17 2
19 8 18 1
20 16 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 16 23 1
26 21 24 1
27 24 25 1
28 25 26 1
29 26 27 1
30 27 28 1
31 28 29 1
32 29 30 1
33 18 31 1
34 31 32 1
35 32 33 1
36 28 34 1
37 34 35 1
38 35 36 1
39 36 37 1
40 30 38 1
41 38 39 1
|